Personalized inhaled bacteriophage therapy for treatment of multidrug-resistant Pseudomonas aeruginosa in cystic fibrosis
Bacteriophage therapy, a method using lytic viruses as antimicrobials, has been shown to reduce antimicrobial resistance in cystic fibrosis patients. A personalized phage therapy strategy was used, resulting in a significant decrease in sputum Pseudomonas and improved predicted FEV1 levels. The study suggests that this personalized, nebulized phage therapy strategy could potentially impact clinical and microbiologic endpoints, but further research is needed to evaluate its effectiveness in larger clinical trials.
AMR NEWS
Your Biweekly Source for Global AMR Insights!
Stay informed with the essential newsletter that brings together all the latest One Health news on antimicrobial resistance. Delivered straight to your inbox every two weeks, AMR NEWS provides a curated selection of international insights, key publications, and the latest updates in the fight against AMR.
Don’t miss out on staying ahead in the global AMR movement—subscribe now!